Wemos in EenVandaag: patent protection Covid-19 vaccine affects low- & middle-income countries

It was a much-needed optimistic headline in recent days: the developments around the pharmaceutical company Pfizer’s new COVID-19 vaccine are in the final stages. However, Pfizer has so far refused to give up the vaccine’s patent protection. This limits production and increases the price per vaccine – threatening access and distribution in low- and middle-income countries in particular. On November 20, Wemos’ global health advocate Tom Buis held an interview about this news in the Dutch programme EenVandaag.

Read more here (Dutch).

Photo: EenVandaag

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent News items

Milestone: research institute shares patents and know-how globally through C-TAP

24-11-2021

Wemos is delighted that the Spanish National Research Council (CSIC) shares its intellectual property and know-how for the production of its Covid-19 diagnostic tool with the Covid-19 Technology Access Pool (C-TAP) of the World Health Organization (WHO). As such, CSIC permits all qualified manufacturers worldwide to make the product and distribute it to any country in the world, royalty-free for low- and middle-income countries. This is the first global, non-exclusive license for a Covid-19 innovation and thus a milestone for equal access to medical products.

Continue reading

Pfizer’s knowledge sharing on antiviral is positive step, but more is needed

16-11-2021

The US pharmaceutical company Pfizer will share its intellectual property and know-how for the production of its Covid-19 pill in the Medicines Patent Pool (MPP). The company is following the example of Merck & Co (MSD) that recently announced the same. This is an important step in the right direction to enhance global access to medical products against Covid-19. Wemos is calling on Pfizer and other vaccine makers to do the same for their vaccines.

Continue reading